Susumu Sato Japan

Susumu Sato, MD, PhD, is an Associate Professor at Kyoto University Graduate School of Medicine and Kyoto University Hospital, Japan. He specializes in respiratory physiology, COPD, pulmonary rehabilitation, and sleep-disordered breathing, with a focus on imaging-based phenotyping and skeletal muscle dysfunction/sarcopenia. His work integrates clinical cohorts and real-world data to advance treatable-traits approaches and patient-centered outcomes. He serves as Head-Elect of the Assembly of Respiratory Structure and Function, Asian Pacific Society of Respirology, and is a Board Director of the GOLD Japan Committee.
Job Title
Associate Professor
Faculty / Department / Division
Department of Respiratory Care and Sleep Control Medicine
Institution / Organisation
Graduate School of Medicine, Kyoto University

20 November 2026, Friday

Time Session
09:30
11:00
  • Ahmad Izuanuddin Ismail Chairperson Malaysia
  • David Halpin Speaker United Kingdom
  • Antonio Anzueto Speaker United States
  • Wisia Wedzicha Speaker United Kingdom
    This presentation will review aspects of COPD exacerbation management in the GOLD 2027 report.
  • Pang Yong Kek Speaker Malaysia
    Title: Leveraging Digital Tools in COPD Management for 2027 & Beyond Routine outpatient management of COPD faces a double deficit: up to 70% of patients make critical inhaler errors, with real-world adherence below 50%, whilst fewer than 3% complete centre-based pulmonary rehabilitation (PR). Digital healthcare addresses this through two synergistic pillars: connected smart inhalers—which enhance adherence by 22%–35% and reduce exacerbations by 17%–30% via objective flow and technique tracking—and digital therapeutics like myCOPD and Kaia COPD, which improve exercise capacity (+57.68 m 6MWD) with outcomes non-inferior to in-person PR. Remote Therapeutic Monitoring (RTM) billing frameworks establish clinical and financial viability by reimbursing multidisciplinary management of non-physiological data, medication adherence, and patient-reported outcomes. Looking toward 2027, multi-modal data fusion—integrating wearable vitals, acoustic cough biomarkers, and smart inhaler actuations—enables machine learning algorithms to forecast acute exacerbations up to 7 days ahead with 92% accuracy, aligning with recent GOLD strategy updates on early phenotypes (Pre-COPD/PRISm) and AI integration. Crucially, digital tools fail in isolation: patient engagement drops to 20% without supervision but exceeds 85% within a structured "clinician-in-the-loop" model, proving human clinical oversight remains essential for successful digital transformation.
  • Ahmad Izuanuddin Ismail Chairperson Malaysia
    Pang Yong Kek Chairperson Malaysia
Ballroom 1, Lower Ground Floor
12:00
13:00
Sponsored by Orient EuroPharma
Mat Zuki Bin Mat Jaeb Chairperson Malaysia
Ballroom 1, Lower Ground Floor

21 November 2026, Saturday

Time Session
08:30
09:00
Advancing COPD Care: From Phenotypes to Targeting Treatable Traits Through Precision Medicine
Marc Miravitlles Speaker Spain
Lalitha Pereirasamy Chairperson Malaysia
"Advancing COPD Care: From Phenotypes to Targeting Treatable Traits Through Precision Medicine Chronic obstructive pulmonary disease (COPD) is a heterogeneous condition characterised by substantial variability in clinical presentation, underlying biological mechanisms, disease trajectory and response to treatment. This heterogeneity has challenged the traditional approach of classifying patients according to fixed clinical phenotypes and applying largely uniform treatment strategies. Increasing evidence supports a shift towards precision medicine, in which treatment decisions are guided by the identification of individual, measurable and clinically relevant treatable traits. The concept of treatable traits represents an evolution from phenotype-based classification towards a multidimensional assessment of the patient. Rather than assigning patients to mutually exclusive categories, this approach recognises that several clinically relevant traits may coexist within the same individual and may change over time. These traits can encompass pulmonary characteristics, such as airflow limitation, hyperinflation, emphysema, chronic bronchitis, bronchiectasis and chronic bronchial infection, as well as systemic and extrapulmonary features including cardiovascular disease, frailty, osteoporosis, skeletal muscle dysfunction, anxiety and depression, and physical inactivity. Importantly, treatable traits should not simply describe disease characteristics; they should identify clinically relevant abnormalities for which an effective intervention is available. This distinction is particularly relevant as therapeutic options for COPD continue to expand. Blood eosinophil counts, for example, can help identify patients who are more likely to benefit from inhaled corticosteroids and, more recently, from targeted biologic therapies. Similarly, frequent exacerbations, chronic bronchial infection, mucus hypersecretion, pulmonary hyperinflation and physical inactivity may each require different therapeutic strategies, ranging from pharmacological treatment to pulmonary rehabilitation, airway clearance, antimicrobial approaches or interventions aimed at reducing hyperinflation. The emergence of biologic therapies targeting specific inflammatory pathways represents an important step towards precision treatment in COPD. However, precision medicine should not be equated with precision pharmacotherapy. Its broader objective is to integrate clinical characteristics, biomarkers, imaging, physiological measurements, comorbidities, environmental exposures and patient-reported outcomes to construct an individualised disease profile and select interventions according to the dominant treatable traits. Future COPD management will therefore require dynamic rather than static patient characterisation. Treatable traits may evolve with disease progression, exacerbations, treatment and ageing, making repeated assessment essential. Digital health, artificial intelligence, multi-omics and increasingly accessible biomarkers may further improve phenotyping and prediction of treatment response. The transition from phenotypes to treatable traits offers an opportunity to move beyond a one-size-fits-all model of COPD care. The challenge now is to determine which traits are clinically meaningful, how they should be identified and prioritised, and whether treating them translates into better outcomes. Precision medicine in COPD should ultimately be judged not by the sophistication of patient classification, but by its capacity to deliver more effective, personalised and clinically meaningful care."
Ballroom 3, Lower Ground Floor
09:30
10:30
Tan Jiunn Liang Chairperson Malaysia
Yasutaka Nakano Chairperson Japan
  • Asiah Kassim Speaker Malaysia
    Both Technical Standards of Spirometry and Lung Volume by ATS/ERS in 2019 and 2023 highlighted the importance of the equipment, quality assurance of the equipment and training of operator handling the equipment and the test. The technique of spirometry prefers both expiratory and inspiratory, calculation of BEV, acceptability of FEV1 and FVC and not the maneuver, repeatability and quality spirometry and lung volume values. The changes require more trained operator and time for the test to be done with a new equipment for measurement. The clinical application of the usable FEV1 and FVC values for interpretation is helpful in certain group of patients like children. However, the new definition of bronchodilator responsiveness based on predictive value is not adapted by GINA or GOLD 2026 as both definitions in 2005 and 2022 is still comparable.
  • Susumu Sato Speaker Japan
    "Beyond Spirometry: Integrating Morphometry and Mechanics for Precision Medicine Although spirometry remains fundamental to respiratory assessment, conventional indices alone do not fully account for the substantial heterogeneity observed in chronic respiratory diseases. Patients with comparable airflow limitation may exhibit marked differences in symptoms, gas exchange impairment, functional capacity, prognosis, and treatment response. This underscores the need to incorporate additional morphological and physiological dimensions into disease assessment. Flow–volume curves contain valuable yet underutilized information beyond FEV₁ and FEV₁/FVC, including mid- and late-expiratory flows, inspiratory–expiratory relationships, and curve-shape or area-based metrics. When interpreted with careful attention to effort dependence, volume dependence, and technical quality, these features may provide further insight into underlying disease mechanisms. Recent developments in imaging-based morphometry have broadened phenotyping beyond the traditional assessment of emphysema severity. Previous research demonstrated that computed tomography (CT)-derived airway wall dimensions and emphysema provide complementary information regarding pulmonary function, supporting the view that airway and parenchymal abnormalities represent distinct yet interacting contributors to airflow limitation. More recent studies suggest that different CT phenotypes carry distinct clinical implications, with differential associations with longitudinal decline in FEV1 and diffusing capacity, as well as prognosis. In addition, airway structural abnormalities, including airway wall thickening and mucus plugging, may be linked not only to airflow limitation and adverse outcomes, but also to specific disease backgrounds such as a history of asthma. Moreover, the scope of imaging-based morphometry may extend beyond the airways and parenchyma to include extrapulmonary and vascular features, such as muscle dysfunction, thereby providing additional functional and prognostic insights. These findings support an integrated framework in which respiratory disease is understood through the interplay between structural abnormalities and their mechanical consequences. In this presentation, I will discuss how integrating imaging-based morphometry with spirometry and broader physiological assessment may move respiratory medicine beyond a spirometry-centered paradigm toward more precise phenotyping, improved risk stratification, and individualized patient care. "
  • Nguyen Van Tho Speaker Vietnam
    Accurate interpretation of lung function is very important for managing respiratory diseases. Diagnosis and classification of the severity of abnormal lung function tests depend on the reference equations used. The Global Lung Function Initiative (GLI) 2021 reference equations were derived from a large representative sample across the entire age range and different ethnic groups using updated standardized techniques of lung function measurements. However, for the Asia-Pacific region—characterized by immensly different genetic, race, environmental, lifespan and varying healthcare infrastructures—using GLI 2021 reference equations presents diagnostic challenges. Implementation of GLI 2021 in Asian populations requires careful validation against existing "Asian-specific" norms. Research indicates that the application of universal equations can alter the "Lower Limit of Normal" (LLN), potentially impacting the diagnosis of restrictive or obstructive patterns or the impairement of lung diffusion capacity in airways and interstitial lung diseases. The GLI 2021 do not include individual data from all populations in the Asia-Pacific region and do not explicitly consider the factors that may contribute to the observed differences in lung function between populations. GLI DLCO equations and GLI static lung volumes are currently based on measurements predominantly from individuals of European ancestry due to insufficient reference data from other populations. In addition, some institutions in the Asia-Pacific region continue using the old models of lung function tests, which are not suitable for GLI 2021. This presentation will highlight some challenges and potential pitfalls when implementing GLI 2021 in the diverse Asia-Pacific region.
  • Q&A
Ballroom 1, Lower Ground Floor
12:30
13:30
Sponsored by AstraZeneca
Azza Omar Chairperson Malaysia
Ballroom 2, Lower Ground Floor
14:00
15:30
16:30
18:00
19:00
22:00

22 November 2026, Sunday

Time Session
12:00
13:00
Azza Omar Chairperson Malaysia
  • Naoya Tanabe Speaker Japan
    Sarcopenia is an important extrapulmonary manifestation of chronic obstructive pulmonary disease (COPD), contributing to reduced physical function and adverse clinical outcomes. Updated Asian Working Group for Sarcopenia (AWGS) 2025 criteria provide a framework for its assessment. Chest computed tomography (CT) enables evaluation of skeletal muscle quantity and quality, offering additional prognostic information. Particularly, reduced erector spinae muscle density, reflecting intramuscular fat accumulation, is associated with loss of health-related independence, in patients with normal body weight. Recent studies have also demonstrated an association between airway mucus plugging and sarcopenia in COPD. Greater mucus plug burden is associated with reduced exercise capacity, skeletal muscle mass, and fat mass, suggesting potential interactions between pulmonary and systemic impairment. These findings highlight the importance of comprehensive assessment beyond airflow limitation. Early identification of sarcopenia and integrated interventions targeting physical activity, nutrition, and respiratory health may improve long-term outcomes in COPD.
  • Pui Ching Shirley Ngai Speaker Hong Kong
    Chronic obstructive pulmonary disease (COPD) is frequently complicated by sarcopenia, a debilitating condition characterized by the accelerated loss of skeletal muscle mass and functional capacity. Compared with their healthy counterparts, individuals with COPD have a higher prevalence of developing sarcopenia. This disproportionate burden is driven by distinct, disease-specific biological mechanisms. Notably, COPD induces a structural muscle fiber shift from fatigue-resistant oxidative fibers (Type I) to force-predominant glycolytic fibers (Type II). This metabolic shift is fundamentally compounded by decreased capillarization and prominent intramuscular fat infiltration, which collectively compromise oxidative capacity and accelerate functional decline. Previous studies suggest that targeted nutritional intervention is critical in managing this complex phenotype, yet standard dietary guidelines routinely fall short. This presentation summarises the clinical recommendations and discusses how the nutritional supplementation would help and support the management for people with COPD.
  • Soo Chin Chan Speaker Malaysia
    This presentation explores sarcopenia in COPD from a rehabilitation perspective, focusing on how COPD affects skeletal muscle and how exercise training can modify these changes. It highlights the complementary roles of resistance and endurance training, before considering how pulmonary rehabilitation translates physiological improvements into better function and participation. The key message is that exercise targets the muscle, while rehabilitation helps translate these gains into what matters to the patient.
  • Q&A
Ballroom 3, Lower Ground Floor